Busulphan
IDH1 Gene Mutation
University of UtahPhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 89/ 100
Competitive context
4 Active assets in the IDH1 Gene Mutation cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
ag-120 The First Affiliated Hospital of Soochow University | Phase 2 | CCC |
Cyclophosphamide University of Utah | Phase 2 | CCC |
Romidepsin University of Utah | Phase 2 | CCC |
Azacitidine The First Affiliated Hospital of Soochow University | Phase 2 | CCC |
Venetoclax The First Affiliated Hospital of Soochow University | Phase 2 | CCC |
Fludarabine University of Utah | Phase 2 | CCC |
Pamiparib University of California, San Francisco | Phase 1 | CC |
Same molecule, other indications
Busulphan is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →